In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/

Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.

This podcast is developed by cor2ed.com

In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.

NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/

Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.

This podcast is developed by cor2ed.com

Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.

They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/

Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com

What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?

In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer. They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/real-world-evidence-mcrc/

Or go to the video on YouTube: https://youtu.be/knQcsWVqcSA

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?

Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.

En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de ovario.

A medida que se desarrolla la conversación, las expertas explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de ovario y hablan sobre los mejores métodos para minimizar las dificultades preanalíticas.

¿Prefiere ver el video mientras escucha?

Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/

O acceda al video en YouTube: https://youtu.be/HnYacC0wZp0

Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.

Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este podcast fue creado por cor2ed.com

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?

Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de ovário.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de ovário e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/tiUgtzqMD-Q

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?

Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.

En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de próstata.

A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de próstata y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas.

¿Prefiere ver el video mientras escucha?

Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/

O acceda al video en YouTube: https://youtu.be/WR9pX3kNao0

Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP) y de la Asociación Nacional de Coaliciones de Cáncer de Próstata (NASPCC). Puede obtener más información sobre la AMP en https://amp.org y la NASPCC en https://naspcc.org.

Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics.

Este pódcast fue creado por cor2ed.com

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?

Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de próstata.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de próstata e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/Pp-2qMSaOPU

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP) e da Aliança Nacional das Coalizões Estaduais de Câncer de Próstata (NASPCC). Saiba mais sobre a AMP em https://amp.org e sobre a NASPCC em https://naspcc.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics.

Este podcast é desenvolvido pela cor2ed.com